iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of iBio (NASDAQ:IBIO) from a sell rating to a hold rating in a research report report published on Wednesday morning.

iBio Stock Up 6.2%

NASDAQ IBIO opened at $0.85 on Wednesday. iBio has a one year low of $0.56 and a one year high of $6.89.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.